SciSparc Ltd., a biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024, for the purpose of registering 1,013,787 ordinary shares under its 2023 Share Incentive Plan. The Form S-8 registration statement is a necessary step for the company to legally grant stock options and award shares to its employees as part of the incentive plan. The shares will be available for issuance to participants of the plan, which is designed to attract and retain employees and to provide them with a stake in the company's success. The registration statement also includes references to the company's Annual Report and other legal documents that provide additional details about SciSparc's financial and operational status. The company, based in Tel Aviv, Israel, has also made provisions for the indemnification and insurance of its directors and officers, as per Israeli law and its amended and restated articles of association.

SciSparc Ltd., a biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 1, 2024, for the purpose of registering 1,013,787 ordinary shares under its 2023 Share Incentive Plan. The Form S-8 registration statement is a necessary step for the company to legally grant stock options and award shares to its employees as part of the incentive plan. The shares will be available for issuance to participants of the plan, which is designed to attract and retain employees and to provide them with a stake in the company's success. The registration statement also includes references to the company's Annual Report and other legal documents that provide additional details about SciSparc's financial and operational status. The company, based in Tel Aviv, Israel, has also made provisions for the indemnification and insurance of its directors and officers, as per Israeli law and its amended and restated articles of association.